| |
PATENTS (selected examples) |
EP 1076710 B1 |
Factors affecting tumor necrosis factor receptor releasing enzyme activity |
MP8 |
U.S. 7,264,820 |
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
oncology |
U.S. 7,175,839 |
Cancer Immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
oncology |
WO 2007/055979 |
Native TRRE: Protein Implicated In TNF Receptor Shedding For Treating Arthritis And Inflammation |
receptor
regulation |
WO 2005/087947 |
New proteolytic enzymes with enhanced specificity for cytokine receptors |
receptor
regulation |
US 6,955,894 |
Method for producing TNF receptor releasing enzyme |
MP8 |
US 6,930,084 |
Treating arthritis with TNF receptor releasing enzyme |
MP8 |
US 6,911,314 |
Screening for drugs that affect TNF receptor releasing enzyme |
MP8 |
WO 2005/030241 |
Treating inflammatory conditions using an agent that causes cytokine receptor release |
MP8 |
U.S. 6,858,402 |
System for discovering and producing polypeptides that cause TNF receptor shedding |
MP8 |
U.S. 6,593,456 |
Tumor necrosis factor receptor releasing enzyme |
MP8 |
U.S. 6,573,062 |
Method for obtaining modulators of TNF receptor releasing enzyme |
MP8 |
U.S. 6,569,664 |
Native TNF receptor releasing enzyme |
MP8 |
U.S. 6,368,593 |
Enhanced immunogenic cell populations prepared using H2 receptor antagonists |
oncology |
U.S. 6,277,368 |
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
oncology |
U.S. 6,262,033 |
Remedy for diseases associated with NF‑κB |
MP40 |
U.S. 6,207,147 |
Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
oncology |
U.S. 6,203,787 |
Treating tumors using implants comprising combinations of allogeneic cells |
oncology |
U.S. 6,136,306 |
Method for treating tumors |
oncology |
U.S. 5,837,233 |
Method for treating tumors |
oncology |
|